{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:52:27Z","timestamp":1791244347867,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2025GXNSFAA069805"],"award-info":[{"award-number":["2025GXNSFAA069805"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.diagmicrobio.2026.117490","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:02:54Z","timestamp":1780012974000},"page":"117490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Case report:Maribavir for refractory CMV infection in 2 pediatric HSCT recipients"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3301-8383","authenticated-orcid":false,"given":"ShuWen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"OuYang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiTing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiYu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenGuang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianMing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunYan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.diagmicrobio.2026.117490_bib0001","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117490_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Allaw","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117490_bib0003","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell Transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.diagmicrobio.2026.117490_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971156","article-title":"Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation","volume":"13","author":"Cui","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.diagmicrobio.2026.117490_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1287456","article-title":"Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.diagmicrobio.2026.117490_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117490_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2023.100804","article-title":"Incidence of refractory CMV infection with or without antiviral resistance in Spain: a systematic literature review","volume":"38","author":"Aguado","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117490_bib0008","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of Cytomegalovirus (CMV) infection and disease in Transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117490_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117490_bib0010","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkae094","article-title":"Absence of maribavir penetration into the central nervous system: confirmation by multiple cerebrospinal fluid dosages in a solid organ transplant recipient","volume":"79","author":"Luque-Paz","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117490_bib0011","article-title":"Case report: maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke's immune-osseous dysplasia","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117490_bib0012","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000002841","article-title":"Use of Maribavir for multidrug resistant cytomegaloviremia in a pediatric oncology patient","volume":"46","author":"Fisher","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117490_bib0013","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41409-024-02212-7","article-title":"Sequential haplo-identical conditioning transplant regimen for pediatric patients with relapsed or refractory hemophagocytic lymphohistiocytosis","volume":"59","author":"Yue","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117490_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2026.117490_bib0015","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/pharmaceutics16101321","article-title":"Use of specific T lymphocytes in treating cytomegalovirus infection in hematopoietic cell transplant recipients: a systematic review","volume":"16","author":"Bandeira","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117490_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmi.2024.06.020","article-title":"Advances and prospect in herpesviruses infections after haematopoietic cell transplantation: closer to the finish line?","volume":"31","author":"Sassine","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2026.117490_bib0017","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.3390\/v14112370","article-title":"Adoptive immunotherapy for prophylaxis and treatment of cytomegalovirus infection","volume":"14","author":"Ouellette","year":"2022","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117490_bib0018","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117490_bib0019","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117490_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13696","article-title":"Maribavir: mechanism of action, clinical, and translational science","volume":"17","author":"Sun","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2026.117490_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02405-21","article-title":"New perspectives on antimicrobial agents: maribavir","volume":"66","author":"Halpern-Cohen","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2026.117490_bib0022","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.diagmicrobio.2026.117490_bib0023","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.2147\/DDDT.S265644","article-title":"Current perspectives on Letermovir and Maribavir for the management of cytomegalovirus infection in solid organ transplant recipients","volume":"18","author":"Razonable","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117490_bib0024","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing Maribavir with Valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117490_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae469","article-title":"Comparative emergence of Maribavir and Ganciclovir resistance in a randomized phase 3 clinical trial for treatment of cytomegalovirus infection","volume":"231","author":"Chou","year":"2025","journal-title":"J Infect Dis"},{"issue":"Supplement_1","key":"10.1016\/j.diagmicrobio.2026.117490_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piad059","article-title":"Current and emerging antiviral agents in the prevention and treatment of cytomegalovirus in pediatric transplant recipients","volume":"13","author":"Valencia Deray","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117490_bib0027","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40121-025-01159-6","article-title":"Tackling CMV in transplant recipients: past, present, and future","volume":"14","author":"Schlaeffer-Yosef","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117490_bib0028","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/v16081268","article-title":"Antiviral agents for preventing cytomegalovirus disease in recipients of hematopoietic cell transplantation","volume":"16","author":"Jaing","year":"2024","journal-title":"Viruses"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326002403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326002403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:00:50Z","timestamp":1791241250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889326002403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0732889326002403"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117490","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case report:Maribavir for refractory CMV infection in 2 pediatric HSCT recipients","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117490"}}